Posters

Change of the vitreoretinal interface in patients with retinal vein occlusion

Poster Details

First Author: I.Weigele GERMANY

Co Author(s):                                 

Abstract Details



Purpose:

Changes of the vitreomacular interface within 6 months under intravitreal therapy with anti-VEGF or none in patients with retinal vein occlusion in spectral-domain optical coherence tomography

Setting:

A retrospective, observational, clinical study was performed. Patients with central (CRVO) and branch (BRVO) retinal vein occlusion were studied during an observation period of 6 months after initial diagnosis. The medical charts of all 47 patients were enrolled in the study.

Methods:

In serial spectral domain optical coherence tomography (SD-OCT)-analysis three VMI groups were identified, vitreo macular adhesion (VMA), partial vitreo macular detachment (VMPD) and complete vitreo macular detachment (VMD). Patients diagnosed with fundus fluorescein angiography and SD OCT were included. Patients with a history of vitrectomy were excluded. Generalised linear models and repeated measures ANOVAs were used to evaluate the effect of VMI types before and after the time period of 6 months. The mean number of intravitreal injections in complete was 2.51 during this 6 months period. 7 patients had no intravitreal application at all and 40 patients received an intravitreal injection with anti-VEGF.

Results:

A total of 47 eyes of 47 patients (20 female, 27 male) treated with anti-VEGF therapy for macular edema due to RVO were identified. The median age of patients with RVO was 71.47 (SD 11.24).

Conclusions:

VMA was found at 32 patients at initial diagnosis and at 27 patients after 6 months ; only 6 patients changed from VMA to VMPD; 1 patient changed from VMA to VMCD (vitreo macular complete detachment). 7 patients developed a gliosis. None of our patients had a VMT (vitreo macular traction). There was a visual improvement in 28 of our patients and a visual impairment in 11 of our patients. In 8 patients the visual acuity remained the same.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy